Celmatix And Reproductive Medicine Associates Of New York Announce Landmark Study Correlating Optimal Hormone Stimulation With Embryo Quality

Large-scale study announced at the American Society for Reproductive Medicine meeting is reassuring news for individuals utilizing IVF

BALTIMORE--(BUSINESS WIRE)--From ASRM Annual Meeting – Celmatix, a personalized medicine company focused on fertility and women’s health, and Reproductive Medicine Associates of New York (RMA-NY), a Manhattan-based fertility center with an extensive history of providing personalized care for patients requiring reproductive assistance, announced today the results of a large-scale study on the effect of hormone-stimulation, routinely used during in vitro fertilization (IVF) procedures, on embryo quality. The results were presented at the American Society for Reproductive Medicine 2015 Annual Meeting. The study was conducted in response to ongoing controversy in the field whether treatment protocols involving minimal or maximal hormone stimulation dosages lead to better embryo quality and outcomes from IVF procedures.

“We hear from physicians in our network that patients undergoing IVF are often concerned that hormone-stimulation could impact their embryo quality”

The study, which analyzed data from over 13,000 IVF treatment cycles undergone by 7,530 patients at RMA-NY, found that, for the majority of women in the study, increasing hormone stimulation dosages did not decrease embryo quality as measured by pre-implantation genetic screening of embryos for chromosomal abnormalities. In contrast, they found that the mother’s overall fertility potential, as a factor of age and other clinical metrics, was the dominant driver of embryo quality.

“We hear from physicians in our network that patients undergoing IVF are often concerned that hormone-stimulation could impact their embryo quality,” explained Dr. Piraye Yurttas Beim, CEO and founder of Celmatix. “For the first time, we can ask this question in a data-driven way because thousands of patients have undergone pre-implantation genetic screening of their embryos, and we can correlate the rates of chromosomal abnormalities with metrics such as age and hormone stimulation protocols. It was reassuring to see that most women who required higher doses of hormone stimulation to achieve the optimal number of embryos did not have their embryo quality negatively impacted by these protocols. Our work underscores the importance of using data-driven methods to identify the ideal dose that allows a woman to maximize her chances of having a healthy baby through IVF.”

Dr. Alan Copperman, director of the Division of Reproductive Endocrinology and Infertility at Mount Sinai Hospital and medical director of RMA of New York, agreed, stating that, “The game has changed now that we screen embryos for chromosomes prior to transfer. Optimal stimulation is defined as not the amount of medications, but as the right stimulation dosage and protocol to create a healthy embryo and a healthy baby. I applaud Celmatix for using data to help our patients reach success in their fertility journey.”

About Celmatix
Celmatix is a personalized medicine company that uses big data and predictive analytics to help individuals who are struggling to have a baby make informed decisions. Founded in 2009 and based in New York City, Celmatix is disrupting the way women approach their lifelong fertility journey by empowering them through science and technology. The company’s flagship Polaris product, in use at top fertility clinics across the country, is the world’s first analytics platform for optimizing fertility. Celmatix also has an active research and development program dedicated to decoding the genetic basis of fertility potential. For more information, visit www.celmatix.com.

About Reproductive Medicine Associates of New York
Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a national and international leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training, RMA of New York consistently reports IVF success rates to the Society for Assisted Reproductive Technology (SART) and the Center for Disease Control and Prevention (CDC) and is internationally recognized for achieving high success rates in the treatment of infertility. RMA of New York maximizes access to care by helping patients explore all insurance coverage and financing options available for treatment. RMA of New York is sensitive to the needs of the LGBT community, women choosing single or same-sex motherhood, as well as women interested in elective fertility preservation. Headquartered in midtown Manhattan, RMA of New York has patient care facilities throughout New York City, as well as in Brooklyn, Garden City, Westchester, and abroad in Mexico City. For more information, please visit www.rmany.com.